Clinical study on the efficacy and safety of Yangxin Decoction in the treatment of angina pectoris (qi stagnation and blood stasis type) with anxiety and depressio

Phase 1

• Conditions: Angina pectoris

• Registration Number: ITMCTR2000003621
• Lead Sponsor: Shanghai Municipal Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. According to the diagnostic criteria of Western medicine for coronary heart disease (one of the following criteria is met):
(1) he has received coronary revascularization therapy, including percutaneous coronary intervention and coronary artery bypass grafting;
(2) coronary angiography or coronary CT angiography results show that at least one coronary artery is narrow and the lumen stenosis is more than 50%;
(3) The patients were diagnosed as coronary heart disease and myocardial ischemia by dynamic or static or drug loading radionuclide myocardial scanning;
(4) having a clear history of myocardial infarction in the past. (Note: the results of one of the above four items provided by the tertiary hospital can be used as diagnostic evidence, and the copy is attached to the research medical record.)
2. The results showed that the patients met the diagnostic criteria of Western medicine for stable angina pectoris;
3. they met the syndrome differentiation criteria of qi deficiency and blood stasis in traditional Chinese medicine;
4. outpatients or inpatients aged between 18 and 70 years old (including boundary value);
5. patients of childbearing age agreed to use a medically acceptable non drug measure for contraception or abstinence within 3 months after the last medication;
6. Patients understand and follow the research process, which is sufficient to complete all the tests and examinations required by the protocol, communicate well with the researchers, participate in the trial voluntarily, and sign the informed consent form.

Exclusion Criteria

1. patients with cardiac function grade 3-4 or pulmonary edema;
2. patients with severe primary brain and lung diseases and liver and kidney dysfunction;
3. patients with traditional Chinese medicine allergy;
4. patients with malignant diseases;
5. patients with severe inflammatory diseases;
6. patients with hemorrhagic diseases;
7. malignant arrhythmias;
8. acute coronary syndrome;
9. critical severe hypertension;
10. psychiatric patients;
11. pregnant or lactating women;
12. nearly 1 Participants in other clinical trials within months.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
oninvasive hemodynamic detection;Colour Sonography;electrocardiogram;